Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 8/20 | 0.49 |
| ▸ | TTBK2 | Q6IQ55 | 8/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090337 | 0.92 | TTBK1 (0.43) | TTBK1TTBK2HDAC6 | |
| SCHEMBL1819928 | 0.86 | TTBK1 (0.52) | TTBK1TTBK2HDAC6HPGDS | |
| SCHEMBL18117027 | 0.85 | TTBK1 (0.46) | TTBK1TTBK2HDAC6HPGDS | |
| SCHEMBL16266363 | 0.78 | TTBK1 (0.61) | TTBK1TTBK2HDAC6 | |
| SCHEMBL7589835 | 0.78 | TTBK1 (0.57) | TTBK1TTBK2 | |
| SCHEMBL25069022 | 0.77 | TTBK1 (0.56) | TTBK1TTBK2HDAC6HPGDS | |
| SCHEMBL3533626 | 0.76 | JAK3 (0.58) | TTBK1TTBK2HPGDS | |
| SCHEMBL5569031 | 0.75 | UTS2R (0.39) | — | |
| SCHEMBL22909512 | 0.75 | TTBK1 (0.57) | TTBK1TTBK2HDAC6HPGDS | |
| SCHEMBL8469366 | 0.75 | S1PR2 (0.57) | TTBK1TTBK2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | TTBK1 126/4885TTBK2 242/4885HDAC6 2194/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | TTBK1 114/4885TTBK2 184/4885HDAC6 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.